Despite their impact in the paradigm of disease control, many challenges remain: around two-thirds of IBD patients demonstrate short-term clinical response to anti-TNF therapy and ~40% of patients who initially improve subsequently lose response (9, 10). This evidence concerns the gene TNF and inflammatory bowel disease.